

ORIGINAL ARTICLE - GASTROENTEROLOGY (CLINICAL)

The efficacy of culture-guided *versus* empirical therapy with high-dose proton pump inhibitor as third-line treatment of *Helicobacter pylori* infection: A real-world clinical experience

Jiunn-Wei Wang,^{*,†,‡} Ping-I Hsu,[§] Ming-Hong Lin,[¶] John Kao,^{**} Feng-Woei Tsay,^{††} I-Ting Wu,[§] Chang-Bih Shie[§] and Deng-Chyang Wu^{†,‡}

*Graduate Institute of Clinical Medicine, College of Medicine, [†]Department of Microbiology and Immunology, School of Medicine, College of Medicine, Kaohsiung Medical University, [‡]Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, ^{††}Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, [†]Department of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung City, [§]Division of Gastroenterology, Department of Internal Medicine, An Nan Hospital, China Medical University, Tainan, Taiwan; ^{**}Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan, USA

Key words

antibiotic resistance, *Helicobacter pylori*, high-dose proton pump inhibitor, susceptibility-guided therapy.

Accepted for publication 3 July 2022.

Correspondence

Deng-Chyang Wu, Division of Gastroenterology, Department of Medicine, Kaohsiung Medical University Hospital and College of Medicine, Kaohsiung Medical University.

Email: dechwu@yahoo.com

Ping-I Hsu, Division of Gastroenterology, Department of Internal Medicine, An Nan Hospital, China Medical University, Tainan, Taiwan.

Email: williamhsup@yahoo.com.tw

[Correction added on 22 August 2022, after first online publication: The affiliations indicated by the symbols, ^{†,‡}, have been added for Jiunn-Wei Wang. Symbols for subsequent affiliations were updated to adjust for these additions.]

Introduction

Helicobacter pylori (*H. pylori*), one of the most prevalent pathogens in the world, is an important pathogen that colonizes the human gastric mucosa and affects more than half of the world's population.¹ Although most infected individuals will be asymptomatic throughout their lives, *H. pylori* infection confers a 1–10% risk of developing gastric or duodenal ulcers, 0.1–3% risk of developing gastric adenocarcinoma, and < 0.01% of developing mucosa-associated lymphoid tissue (MALT) lymphoma.²

Nevertheless, eradicating *H. pylori* has become a rising challenge for physicians worldwide owing to the growing prevalence of global antibiotic resistance.³ The practice guidelines, including the Maastricht V/Florence Consensus and the American College of

Abstract

Background and Aim: Most consensus recommend culture-guided therapy as third-line *Helicobacter pylori* treatment. This study aimed to investigate the efficacies of culture-guided therapy and empirical therapy with high-dose proton pump inhibitor (PPI) in the *H. pylori* third-line treatment.

Methods: Between August 2012 and October 2021, *H. pylori*-infected patients with at least two failed eradication attempts received anti-*H. pylori* therapy according to the results of antimicrobial sensitivity tests plus high-dose rabeprazole and/or bismuth. They were categorized into three groups: patients who had positive results of culture with equal to or more than three susceptible antibiotics were treated by culture-guided non-bismuth quadruple therapy, patients who had positive results of culture with one or two susceptible antibiotics were treated by culture-guided bismuth-containing therapy, and patients who had a negative result of culture were treated by an empirical therapy with high-dose rabeprazole plus amoxicillin, tetracycline and levofloxacin. A post-treatment assessment was conducted at week 8.

Results: We recruited 126 patients. The eradication rates of culture-guided non-bismuth quadruple therapy ($n = 50$), culture-guided bismuth-containing therapy ($n = 46$) and empirical therapy ($n = 30$) were 84.0%, 87.0%, and 66.7% (95% confidence interval: 73.8–94.2%, 77.3–96.7%, and 49.8–83.6%), respectively. Overall, culture-guided therapy achieved a higher eradication rate than empirical therapy (85.4% vs 66.7%; 95% confidence interval, 0.4% to 37.0%, $P = 0.022$).

Conclusions: Culture-guided therapy with high-dose PPI achieves a higher eradication rate than empirical therapy with high-dose PPI in the third-line treatment of *H. pylori* infection. The eradication rate of rescue therapy with bismuth plus two susceptible antibiotics is not inferior to that with three susceptible antibiotics.

Gastroenterology (ACG), recommend that patients who suffer from multiple treatment failures should undergo *H. pylori* culture and antimicrobial susceptibility testing to individualize the following course of treatment.^{4,5} The Taiwan Consensus also suggests *H. pylori* culture with susceptibility testing or molecular determination of genotype resistance as third-line rescue therapy.⁶ However, there is limited evidence regarding the effectiveness of culture-guided therapy for rescue therapy. Furthermore, most hospitals do not have facilities to perform *H. pylori* cultures and antimicrobial susceptibility tests, and/or the high cost of endoscopically obtaining gastric biopsy specimens for *H. pylori* cultures restricts the clinical application of culture-guided therapy in many countries. Therefore, empirical rescue treatments were chosen as alternative therapies in some clinical conditions.

Previous studies have demonstrated high rates of resistance to clarithromycin and metronidazole in patients who have undergone *H. pylori* eradication therapy.^{7–9} Several studies have revealed that tetracycline, amoxicillin, and levofloxacin are good candidates for antibiotics used in the rescue treatment of *H. pylori* infection.^{7–11} Because bismuth is not available in many hospitals, non-bismuth-based quadruple therapy (NBQT) is often used to salvage treatment of *H. pylori* infection.¹² However, variable eradication rates of NBQT ranging from 72% to 90% for rescue treatment have been reported in different studies.^{9,12,13}

Proton pump inhibitors (PPIs) play an important role in *H. pylori* treatment. They possess anti-*H. pylori* activity and increase the bioavailability and activity of some antibiotics by reducing gastric acid secretion.¹⁴ The minimal inhibitory concentrations (MIC) of most antibiotics against *H. pylori* are dependent on the pH of the environment. Therefore, PPIs are an important component of anti-*H. pylori* regimen because they increase the pH of the stomach, allowing better antimicrobial activity.^{15,16} They are metabolized by the hepatic cytochrome P450 system, particularly S-mephenytoin 40-hydroxylase (*CYP2C19*). Previous studies have reported that the *CYP2C19* homogeneous extensive metabolizer (homEM) genotype is an independent factor for failure of first-line *H. pylori* eradication therapy.^{17,18} High-dose dual therapy consists of high-dose PPI and amoxicillin, which maintain the intragastric pH at a value higher than 6.5 regardless of the *CYP2C19* genotype and maintains a steady plasma concentration of amoxicillin above the MIC for *H. pylori*.^{19,20} The efficacy of the new therapy was significantly higher than that of standard triple therapy.²¹

Currently, it is unclear whether culture-guided therapy is superior to empirical therapy as third-line treatment of *H. pylori* infection. A systematic review reported an unsatisfactory eradication rate of less than 80% with culture-guided therapy as a third-line treatment.²² Whether the suboptimal eradication of culture-guided therapy as the third-line treatment of *H. pylori* infection is related to the rapid metabolism of PPIs in individuals with *CYP2C19* homEMs remains unknown. Therefore, we designed this study to investigate the efficacy of culture-guided and empirical therapies as the third-line treatment of *H. pylori* infection. To maintain a steady plasma concentration of antibiotics regardless of the *CYP2C19* genotype, high-dose PPI was administered in both rescue therapies.

Methods

Study population. The study, a prospective, multicenter, open-label clinical trial was conducted at Kaohsiung Medical University Hospital, Kaohsiung Veterans General Hospital, and Tainan Municipal An Nan Hospital in Taiwan. *H. pylori*-infected adult patients of at least 20 years of age and failure of first-line (standard triple, non-bismuth quadruple, and bismuth quadruple therapies) and second-line eradication treatments (bismuth quadruple, fluoroquinolone-containing triple/quadruple therapies) were recruited for this study. Written informed consent was obtained from all the patients prior to enrollment. Subjects with any of the following criteria were excluded from this trial: (i) known allergy to any antibiotic or PPIs in our study or, (ii) previous gastric surgery, (iii) pregnant or lactating women, and (iv)

the use of antibiotics within the prior 4 weeks. This trial was approved by the Institutional Review Board of Kaohsiung Medical University Hospital (KMUHIRB-E (II)-20,150,091), Kaohsiung Veterans General Hospital (VGHKS13-CT12-17), and Tainan Municipal An Nan Hospital (TMANH110-REC015).

Procedures. Before enrollment, the status of *H. pylori* infection was determined by (i) positive results of both rapid urease test and histology or (ii) positive culture results. Patients with positive results in one of these tests were eligible for enrollment. Complete medical history and demographic data of all patients were acquired, including age, sex, medical history, history of smoking, and alcohol, coffee, and tea consumption, and a standard questionnaire was completed by each patient on enrollment.

All eligible patients underwent esophagogastroduodenoscopy, and two gastric specimens were obtained from the lesser curvature of the antrum and the corpus by endoscopic biopsy.²³ The biopsy specimens were then cultured on Brucella chocolate agar with 7% sheep blood, incubated for 7 days under microaerobic conditions, and the *H. pylori* strains were tested for antibiotic susceptibility using the E-test (AB Biodisk, Solna, Sweden). *H. pylori* strains with MIC > 0.5 µg/mL, > 1 µg/mL, > 1 µg/mL, > 4 µg/mL, and > 8 µg/mL were considered to be resistant to amoxicillin, clarithromycin and levofloxacin, tetracycline, and metronidazole, respectively.²¹

Eligible patients received anti-*H. pylori* therapy based on the results of culture and antimicrobial sensitivity tests. In patients with a positive result of culture and *H. pylori* strains susceptible to three or more antibiotics, a non-bismuth regimen containing a high-dose PPI plus three susceptible antibiotics was used to treat *H. pylori* infection. In those with a positive result of culture and *H. pylori* strains susceptible to only one or two antibiotics, a bismuth-containing regimen containing a high-dose PPI, bismuth and susceptible antibiotics was applied as rescue treatment. In patients with a negative culture results, an empirical therapy containing a high-dose PPI plus amoxicillin, tetracycline and levofloxacin was administered to treat *H. pylori* infection. Therefore, the treatments were categorized into three groups: (i) 14-day culture-guided non-bismuth quadruple therapy (rabeprazole [Pariet E.C.; Bushu Pharm, Saitama-ken, Japan] 20 mg q.d.s. and three effective antibiotics) for patients with a positive culture result *H. pylori* strains susceptible to at least three antibiotics; (ii) 14-day culture-guided bismuth-containing therapy (rabeprazole 20 mg q.d.s., tripotassium dicitrate bismuthate [KCB; Swiss Pharm, Tainan, Taiwan] 300 mg q.d.s., and all the effective antibiotics) for patients with a positive result of culture and *H. pylori* strains susceptible to only one or two antibiotics; and (iii) 14-day empirical therapy (rabeprazole 20 mg q.d.s., amoxicillin [amoxicillin trihydrate; Yung Shin Pharm, Taichung, Taiwan] 500 mg q.d.s., tetracycline [tetracycline HCl; Taiwan Veterans Pharm, Chungli, Taiwan] 500 mg q.d.s. and levofloxacin [Cravit; Sanofi-Aventis, Taoyuan, Taiwan] 500 mg o.d.) for patients with a negative result of culture.

The patients were requested to return in the second week to assess drug adherence and adverse effects. Adverse events were assessed by a research assistant according to the defined criteria. The patients were informed of the common side effects of the

study drugs and were asked to record these symptoms in the provided diaries. Adverse events were assessed according to a four-point scale: none, mild (discomfort annoying but not interfering with daily life), moderate (discomfort sufficient to interfere with daily life), and severe (discomfort resulting in discontinuation of eradication therapy).²⁴ Drug adherence was assessed by pill counts after treatment. Adherence was graded as good if the patients took equal to or more than 80% of the total medication, or as poor otherwise.²⁴

Post-treatment *H. pylori* status was determined by ¹³C-urea breath tests using an infrared spectrometer at the end of week 8. All patients were asked to stop treatment with PPI and histamine-2 blockers for at least 2 weeks before undergoing esophagogastroduodenoscopy or urea breath tests. ¹³C-urea breath tests were performed after an overnight fast using the Proto Pylori kit (Isodiagnostika, Montreal, Canada). The 75 mg ¹³C-urea manufactured by the Institute of Nuclear Energy Research in Taiwan, was dissolved in water. Baseline and 30 min breath samples were assayed with an infrared spectrometer that produced computer-generated results at Kaohsiung Medical University Hospital and Kaohsiung Veterans General Hospital. Positive results were defined as a computer-generated $\delta^{13}\text{CO}_2$ value ≥ 4 units and negative results as < 2.5 units.¹⁰ Successful eradication was defined as a negative result of the ¹³C-urea breath test. Patients with intermediate delta values (2.5–4 units) underwent another ¹³C-urea breath test at least 4 weeks later until the results became conclusive.

Statistical analysis. The primary endpoint of the study was *H. pylori* eradication rate. Intention-to-treat (ITT) and per-protocol (PP) analyses were conducted. The ITT population included all randomized subjects who received at least one dose of the eradication drugs. Patients whose infection status was unknown following treatment were considered to have treatment failures in the ITT analysis. The PP analysis excluded patients with unknown *H. pylori* status following therapy and those with poor drug adherence. The secondary endpoints were the frequency of adverse events and drug adherence. A χ^2 test with or without the Yates correction for

continuity and Fisher's exact test were used where appropriate to compare the major outcomes between the groups. Statistical significance was set at $P < 0.05$. SPSS (version 25 for Microsoft Windows) was used for all statistical analyses.

Results

Characteristics of the patients. Between August 2012 and October 2021, 137 patients with failure of first- and second-line eradication were initially assessed for eligibility, and 126 of them were recruited in our study. Figure 1 demonstrates the patient composition. Ninety-six patients with the positive culture results underwent culture-guided non-bismuth quadruple therapy ($n = 50$) or culture-guided bismuth-containing therapy ($n = 46$). The other patients ($n = 30$) with negative culture results were treated with empirical therapy.

The clinical characteristics of the patients administered culture-guided or empirical therapy are summarized in Table 1. The previous failed eradication regimens of all patients were listed in Table S1. The two patient groups had comparable characteristics in terms of age, sex, and history of peptic ulcer disease, and alcohol, coffee, and tea consumption. The resistance rates for clarithromycin, metronidazole, amoxicillin, tetracycline, and levofloxacin in culture-guided therapy group were 79.2%, 65.6%, 0%, 0%, and 81.3%, respectively.

Eradication rate, drug adherence, and adverse events of culture-guided and empiric therapies in the third-line treatment of *Helicobacter pylori* infection. Table 2 illustrates the major outcomes of culture-guided and empiric therapies in the third-line treatment of *H. pylori* infection. The eradication rates of culture-guided therapy with high-dose rabeprazole and empirical therapy with high-dose rabeprazole were 85.4% (95% confidence interval [CI]: 80.4–92.6%) and 66.7% (95% CI: 49.8–83.6%), respectively. Overall, culture-guided therapy achieved a higher eradication rate than empirical therapy (Difference, 18.7%; 95% CI: 0.4% to 37.0%, $P = 0.022$). PP analysis yielded similar results




Figure 1 Flow diagram of patient allocation.

Table 1 Demographic data of patients

| Characteristics | Culture-guided group | | | Empiric group (n = 30) | P-value [†] |
|-------------------------|---------------------------------|--|--------------|---------------------------|----------------------|
| | Non-bismuth regimen (n = 50) | Bismuth-containing regimen (n = 46) | All (n = 96) | | |
| Age (years) (mean ± SD) | 54.3 ± 10.6 | 53.3 ± 9.1 | 53.8 ± 9.8 | 57.5 ± 10.8 | 0.086 |
| Gender (male/female) | 26/24 | 12/34 | 38/58 | 13/17 | 0.715 |
| Smoking | 8 (16.0%) | 6 (13.0%) | 14 (14.6%) | 0 (0.0%) | 0.022 |
| Alcohol consumption | 3 (6.0%) | 2 (4.3%) | 5 (5.2%) | 0 (0.0%) | 0.337 |
| Ingestion of coffee | 24 (48.0%) | 13 (28.3%) | 37 (38.5%) | 7 (23.3%) | 0.127 |
| Ingestion of tea | 16 (32.0%) | 12 (26.1%) | 28 (29.2%) | 6 (20.0%) | 0.323 |
| Peptic ulcer disease | 22 (44.0%) | 18 (39.1%) | 40 (41.7%) | 10 (33.3%) | 0.415 |
| Antibiotic resistance | | | | | |
| Clarithromycin | 33 (66.0%) | 43 (93.5) | 76 (79.2%) | - | - |
| Metronidazole | 18 (36.0%) | 45 (97.8%) | 63 (65.6%) | - | - |
| Amoxicillin | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | - | - |
| Tetracycline | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | - | - |
| Levofloxacin | 37 (74.0%) | 41 (89.1) | 78 (81.3%) | - | - |

[†]Comparison between culture-guided therapy and empirical therapy.

Table 2 Outcomes of culture-guided and empirical rescue therapies as the third-line treatment of *Helicobacter pylori* infection

| Outcome | Culture-guided therapy | | | Empiric therapy (n = 30) | P-value* |
|--------------------|---------------------------------|--|----------------------------|----------------------------|----------|
| | Non-bismuth regimen (n = 50) | Bismuth-containing regimen (n = 46) | All (n = 96) | | |
| Eradication rate | | | | | |
| Intention-to-treat | 84.0% (42/50) (73.8–94.2%) | 87.0% (40/46) (77.3–96.7%) | 85.4% (82/96) (80.4–92.6%) | 66.7% (20/30) (49.8–83.6%) | 0.022 |
| Per-protocol | 87.5% (42/48) (80.8–93.8%) | 88.9% (40/45) (82.4–94.5%) | 88.2% (82/93) (83.5–94.0%) | 68.0% (17/25) (49.7–86.3%) | 0.015 |
| Drug adherence | 96.0% (48/50) (92.1–98.1%) | 97.8% (45/46) (94.7–98.9%) | 95.8% (92/96) (91.8–99.8%) | 83.3% (25/30) (70.0–96.6%) | 0.035 |
| Adverse events | 42.0% (21/50) (28.3–55.7%) | 19.6% (9/46) [†] (8.13–31.1%) | 31.3% (30/96) (17.9–44.7%) | 43.3% (13/30) (28.8–64.6%) | 0.122 |

[†]Bismuth containing subgroup had a lower frequency of adverse events than non-bismuth subgroup ($P = 0.018$).

*Comparison between culture-guided therapy and empirical therapy.

(88.2% vs 68.0%; $P = 0.015$). All patients were included in the ITT analysis for adverse events and adherence. Patients administered culture-guided therapy had better drug adherence than those administered empiric therapy (95.8% vs 83.3%, respectively; $P = 0.035$). The two therapies exhibited similar frequencies of overall adverse events (31.3% vs 43.3%; $P = 0.122$). Table 3 lists the profiles of adverse events of the two eradication treatments. The empirical therapy group had a higher frequency of nausea than the culture-guided therapy group (40.0% vs 17.7%; $P = 0.011$). No significant differences were observed between the groups in terms of the frequencies of other adverse events.

Intra-group analysis for eradication rate, drug adherence, and adverse events in culture-guided therapy patients. Table 2 also displays the intra-group comparison of the major outcomes of patients administered NBQT or bismuth-containing therapy in the culture-guided therapy group. The detail eradication rates of each specific therapy of NBQT and bismuth-containing therapies were listed in the Table 4 and Table 5, respectively. The most commonly prescribed antibiotics combination in NBQT was amoxicillin plus tetracycline and metronidazole (31/50), and that in bismuth-containing therapies was amoxicillin plus tetracycline (35/46). Overall, NBQT subgroup

and bismuth-containing subgroup had comparable eradication rates in ITT (84.0% vs 87.0%; $P = 0.682$) and PP analysis (87.5% vs 88.9%). However, the NBQT subgroup had a higher frequency of adverse events than the bismuth-containing subgroup (42.0% vs 19.6%; $P = 0.018$). There were no significant differences in drug adherence between the two patient groups (96.0% vs 97.8%; $P > 0.999$).

Discussion

In the current study, we conducted a prospective trial to investigate the efficacy of culture-guided and empirical therapy with high-dose PPI as the third-line treatment of *H. pylori* infection. The results demonstrate several novel findings. First, culture-guided therapy with high-dose PPI achieved a higher eradication rate than empirical therapy with high-dose PPI as the third-line treatment of *H. pylori* infection. Second, rescue therapy with bismuth plus two or three antibiotics, to which *H. pylori* was sensitive, had comparable eradication rates in the treatment of refractory *H. pylori* infection, but the bismuth with two antibiotics exhibited a lower frequency of adverse events than the bismuth with three antibiotics (19.6% vs 42.0%; $P = 0.018$). Third, a significant number (15%) of infected subjects failed to eradicate *H. pylori* infection, although the antibiotics in their rescue regimens

Table 3 Adverse events of culture-guided and empirical rescue therapies as the third-line treatment of *Helicobacter pylori* infection

| | Culture-guided group | | | Empiric group (n = 30) | P-value [†] |
|----------------|------------------------------|-------------------------------------|--------------|------------------------|----------------------|
| | Non-bismuth regimen (n = 50) | Bismuth-containing regimen (n = 46) | All (n = 96) | | |
| Abdominal pain | 6 (12.0%) | 0 (0.0%) | 6 (6.25%) | 1 (3.33%) | > 0.999 |
| Diarrhea | 4 (8.0%) | 0 (0.0%) | 4 (4.17%) | 1 (3.33%) | > 0.999 |
| Constipation | 1 (2.0%) | 0 (0.0%) | 1 (1.04%) | 0 (0.00%) | > 0.999 |
| Anorexia | 0 (0.0%) | 0 (0.0%) | 0 (0.00%) | 0 (0.00%) | NA |
| Nausea | 12 (24.0%) | 5 (10.9%) | 17 (17.71%) | 12 (40.00%) | 0.011 |
| Vomiting | 3 (6.0%) | 2 (4.3%) | 5 (5.21%) | 2 (6.67%) | 0.671 |
| Skin rash | 0 (0.0%) | 0 (0.0%) | 0 (0.00%) | 0 (0.00%) | NA |
| Headache | 3 (6.0%) | 0 (0.0%) | 3 (3.13%) | 1 (3.33%) | > 0.99 |
| Dizziness | 3 (6.0%) | 2 (4.3%) | 5 (5.21%) | 2 (6.67%) | 0.671 |
| Bad taste | 3 (6.0%) | 0 (0.0%) | 3 (3.13%) | 1 (3.33%) | > 0.99 |
| Fatigue | 3 (6.0%) | 1 (2.2%) | 4 (4.17%) | 3 (10.00%) | 0.356 |

NA, not applicable.

[†]Comparison between culture-guided therapy and empirical therapy.

Table 4 The eradication rate of each specific therapy in patients receiving non-bismuth quadruple therapies for *Helicobacter pylori* infection

| | Non-bismuth quadruple therapy | | | |
|--------------------|-------------------------------|--------------|--------------|--------------|
| | RATM (n = 31) | RATL (n = 7) | RACT (n = 9) | RACM (n = 3) |
| Eradication rate | | | | |
| Intention-to-treat | 96.8% (30/31) | 85.7% (6/7) | 55.6% (5/9) | 66.7% (2/3) |
| Per-protocol | 96.7% (29/30) | 85.7% (6/7) | 62.5% (5/8) | 66.7% (2/3) |

RATM, rabeprazole + amoxicillin + tetracycline + metronidazole; RATL, rabeprazole + amoxicillin + tetracycline + levofloxacin; RACT, rabeprazole + amoxicillin + clarithromycin + tetracycline; RACM = rabeprazole + amoxicillin + clarithromycin + metronidazole.

Table 5 The eradication rate of each specific therapy in patients receiving bismuth-containing third-line treatment for *Helicobacter pylori* infection

| | Bismuth-containing therapies | | | | | |
|--------------------|------------------------------|--------------|---------------|--------------|--------------|--------------|
| | RBTM (n = 1) | RBTL (n = 4) | RBAT (n = 35) | RBAC (n = 4) | RBAM (n = 1) | RBAL (n = 1) |
| Eradication rate | | | | | | |
| Intention-to-treat | 100% (1/1) | 100% (4/4) | 82.9% (29/35) | 100% (4/4) | 100% (1/1) | 100% (1/1) |
| Per-protocol | 100% (1/1) | 100% (4/4) | 85.3% (29/34) | 100% (4/4) | 100% (1/1) | 100% (1/1) |

RBTM, rabeprazole + tripotassium dicitrato bismuthate + tetracycline + metronidazole; RBTL, rabeprazole + tripotassium dicitrato bismuthate + tetracycline + levofloxacin; RBAT, rabeprazole + tripotassium dicitrato bismuthate + amoxicillin + tetracycline; RBAC, rabeprazole + tripotassium dicitrato bismuthate + amoxicillin + clarithromycin; RBAM, rabeprazole + tripotassium dicitrato bismuthate + amoxicillin + metronidazole; RBAL, rabeprazole + tripotassium dicitrato bismuthate + amoxicillin + levofloxacin.

were effective *in vitro*, and high-dose PPI was administered to increase antimicrobial activity.

Currently, most national and international consensus recommend culture-guided therapy as third-line treatment of *H. pylori* infection.^{4–6} However, whether culture-guided therapy is superior to empirical therapy as third-line treatment of *H. pylori* infection remains unclear. Yu et al. conducted a prospective trial of 200 patients and demonstrated that culture-guided therapy could prove highly efficacious (overall eradication rate: 94.5%) in multidrug-resistant *H. pylori* infection.²⁵ However, a systematic review and meta-analysis showed that the cure rates of susceptibility-based treatment as a third-line therapy were not superior to empirical therapies, and the unsatisfactory mean cure rate

of susceptibility-based treatment was reported to be 72%.²⁶ Possible explanations for the discrepancies in the efficacy of culture-guided therapy included divergent patient compliance, different treatment durations, and variable frequencies of *CYP2C19* genotypes.^{26,27}

The MIC of most antibiotics against *H. pylori* are dependent on the pH of the environment. PPIs possess anti-*H. pylori* activity and can increase the bioavailability and activity of antibiotics by reducing gastric acid secretion. In this study, we applied high-dose rabeprazole to maintain the intragastric pH at a value higher than 6.5, regardless of the *CYP2C19* genotype. The data of this prospective trial showed that culture-guided therapy with high-dose PPI had a markedly higher eradication rate than empirical therapy

with high-dose PPI, in both ITT (85.4% vs 66.7%) and PP analysis (88.2% vs 68.0%). Additionally, the patients who underwent culture-guided therapy had better drug adherence than those who underwent empirical therapy (95.8% vs 83.3%; $P = 0.035$). These novel findings in this study support the recommendations made, concerning the third-line treatment of *H. pylori* infection, by most national and international consensus guidelines.^{4–6}

In this study, the patient groups receiving regimens containing three antibiotics (the empirical therapy group and the non-bismuth subgroup in the culture-guided group) had higher frequencies of adverse effects than the patient group receiving regimens containing only two antibiotics (the bismuth containing subgroup) (43.3% & 42.0% vs 19.6%). The drug adherence in the culture-guided group was higher than that in the empirical group, probably due to the fewer adverse events of the bismuth containing subgroup.

In the current study, the frequencies of antibiotic resistance to clarithromycin, metronidazole, amoxicillin, tetracycline, and levofloxacin in *H. pylori* strains isolated from patients with failure of at least two anti-*H. pylori* therapies were 79.2%, 65.6%, 0%, 0%, and 81.3%, respectively. The results were similar to the antibiotic resistant data of a multicentre study from Taiwan.²⁸ In that study, the resistant rates of *H. pylori* to amoxicillin, levofloxacin and tetracycline in the third-line treatment from 2017 to 2019 were 3%, 84%, and 1%, respectively. Another randomized controlled trial from Taiwan showed that the resistant rates of *H. pylori* to amoxicillin, levofloxacin, and tetracycline in the third-line treatment were 14%, 59%, and 6%, respectively.⁹ In general, the resistant frequencies of amoxicillin and tetracycline of *H. pylori* strains in third-line eradication therapy are less than 15% in Taiwan, and the resistant frequency of levofloxacin are higher than 50%.

In this study, only 50 (52.1%) of the 96 *H. pylori* strains with culture data had equal to or more than three susceptible antibiotics. Because bismuth salts have a synergistic effect with antibiotics by destroying bacteria like an antiseptic,^{29,30} we applied tripotassium dicitrate bismuthate to increase the effects of antibiotics in patients who had only two susceptible antibiotics. The results demonstrated that the eradication rate of rescue therapy with bismuth plus two antibiotics was not inferior to that with three antibiotics to which *H. pylori* was susceptible (87.0% vs 84.0%). Additionally, rescue therapy with bismuth plus two antibiotics, to which *H. pylori* was susceptible, had a lower frequency of adverse events than rescue therapy with three antibiotics as the third-line treatment of *H. pylori* infection (19.6% vs 42.0%). The data indicate that a salvage regimen consisting of a PPI, bismuth salt, and two antibiotics to which *H. pylori* is susceptible is a good choice for the treatment of refractory *H. pylori* infection.

This study has some limitations. First, the current study was not a double-blind placebo-controlled trial in which selection bias would be minimized. Patients who underwent culture-guided therapy and empirical therapy might have different antibiotic susceptibility profiles. However, this work provided real-world data on culture-guided and empirical therapies as the third-line treatment of *H. pylori* infection. Second, the current study was conducted in a single country, so the results need to be validated in different countries where there are distinct patterns of antibiotic resistance and *CYP2C19* genotypic polymorphism. Third, a significant number (15%) of infected subjects failed to eradicate *H. pylori* infection, although the antibiotics in their rescue regimens were

effective *in vitro*, and high-dose PPI was administered to increase antimicrobial activity. The causes of eradication failure in patients administered antibiotics to which *H. pylori* is susceptible remain to be identified. Fourth, the culture-guided group and empirical therapy group might have different antibiotic susceptibility profiles. However, antibiotic resistance data are unavailable sometimes in clinical practice if patients refuse to receive endoscopy for culture or the result of *H. pylori* culture is negative. The current study clearly show that the eradication rate of an empirical therapy with a PPI, amoxicillin, tetracycline, and levofloxacin in patients with refractory *H. pylori* infection and unavailable antibiotic resistance data was lower than that of culture-guided therapy in patients with refractory *H. pylori* infection and available antibiotic resistance data. It is therefore important to for physicians to get antibiotic susceptibility data in the third-line therapy for *H. pylori* infection. Fifth, it was underpowered to make an adequate analysis to investigate the association between eradication outcome and previous eradication regimens in each treatment arm because the recruited patients in this study received more than 10 kinds of treatment combinations of first-line and second-line therapies (Table S1).

In conclusion, culture-guided therapy with high-dose PPI achieved a higher eradication rate than empirical therapy with high-dose PPI as the third-line treatment of *H. pylori* infection. The eradication rate of rescue therapy with bismuth plus two antibiotics to which *H. pylori* was susceptible was not inferior to that with three antibiotics. Additionally, rescue therapy with bismuth plus two antibiotics exhibited a lower frequency of adverse events than rescue therapy with bismuth plus three antibiotics.

Acknowledgments

The authors are indebted to study nurses at the An Nan Hospital, Kaohsiung Medical University and Kaohsiung Veterans General Hospital. This study was funded by the An Nan Hospital (Grant Numbers: ANHRF 109-13, ANHRF 109-38, ANHRF 110-17, and ANHRF 110-43), Tainan, Taiwan, and Ministry of Science and Technology, Executive Yuan, Taiwan, ROC (Grant numbers: MOST110-2314-B039-045 and MOST109-2314-B039-053) and Kaohsiung Medical University Hospital (Grant number: KMUH108-8R01). [Correction added on 15 August 2022, after first online publication: Funding from Kaohsiung Medical University Hospital has been added to the Acknowledgments.]

References

- Hooi JKY, Lai WY, Ng WK *et al.* Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. *Gastroenterology* 2017; **153**: 420–9.
- McCull KE. Clinical practice. Helicobacter pylori infection. *N. Engl. J. Med.* 2010; **362**: 1597–604.
- Camargo MC, García A, Riquelme A *et al.* The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. *Am. J. Gastroenterol.* 2014; **109**: 485–95.
- Malferteiner P, Megraud F, O'Morain CA *et al.* Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. *Gut* 2017; **66**: 6–30.
- Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. *Am. J. Gastroenterol.* 2017; **112**: 212–39.

- 6 Sheu BS, Wu MS, Chiu CT *et al.* Consensus on the clinical management, screening-to-treat, and surveillance of *Helicobacter pylori* infection to improve gastric cancer control on a nationwide scale. *Helicobacter* 2017; **22**.
- 7 Cao Z, Chen Q, Zhang W *et al.* Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for *Helicobacter pylori* treatment failures: a randomized clinical trial. *Scand. J. Gastroenterol.* 2015; **50**: 1185–90.
- 8 Kuo CH, Hu HM, Kuo FC *et al.* Efficacy of levofloxacin-based rescue therapy for *Helicobacter pylori* infection after standard triple therapy: a randomized controlled trial. *J. Antimicrob. Chemother.* 2009; **63**: 1017–24.
- 9 Liou JM, Chen PY, Luo JC *et al.* Efficacies of genotypic resistance-guided vs empirical therapy for refractory *Helicobacter pylori* infection. *Gastroenterology* 2018; **155**: 1109–19.
- 10 Rendell-Baker L. Nineteenth-century resuscitation apparatus. *Anaesthesia* 1981; **36**: 1058–9.
- 11 Wu IT, Chuah SK, Lee CH *et al.* Five-year sequential changes in secondary antibiotic resistance of *Helicobacter pylori* in Taiwan. *World J. Gastroenterol.* 2015; **21**: 10669–74.
- 12 Jheng GH, Wu IC, Shih HY *et al.* Comparison of Second-Line Quadruple Therapies with or without Bismuth for *Helicobacter pylori* Infection. *Biomed. Res. Int.* 2015; **2015**: 163960.
- 13 Huang HT, Wang HM, Yang SC *et al.* Efficacy of a 14-day quadruple-therapy regimen for third-line *Helicobacter pylori* eradication. *Infect Drug Resist.* 2018; **11**: 2073–80.
- 14 Huang CC, Tsai KW, Tsai TJ, Hsu PI. Update on the first-line treatment for *Helicobacter pylori* infection - a continuing challenge from an old enemy. *Biomark Res.* 2017; **5**: 23.
- 15 Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. *Drug Metab. Pharmacokinet.* 2005; **20**: 153–67.
- 16 Kita T, Sakaeda T, Aoyama N *et al.* Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-*Helicobacter pylori* therapy: pharmacokinetic considerations. *Biol. Pharm. Bull.* 2002; **25**: 923–7.
- 17 Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on *H. pylori* eradication rate in dual and triple first-line PPI therapies: a meta-analysis. *Am. J. Gastroenterol.* 2006; **101**: 1467–75.
- 18 Schwab M, Schaeffeler E, Klotz U, Treiber G. CYP2C19 polymorphism is a major predictor for treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication *Helicobacter pylori*. *Clin. Pharmacol. Ther.* 2004; **76**: 201–9.
- 19 Sugimoto M, Furuta T, Shirai N *et al.* Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. *Clin. Pharmacol. Ther.* 2004; **76**: 290–301.
- 20 Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. *Clin. Infect. Dis.* 1998; **26**: 1–10.
- 21 Yang JC, Lin CJ, Wang HL *et al.* High-dose dual therapy is superior to standard first-line or rescue therapy for *Helicobacter pylori* infection. *Clin. Gastroenterol. Hepatol.* 2015; **13**: 895–905.
- 22 Puig I, López-Góngora S, Calvet X *et al.* Systematic review: third-line susceptibility-guided treatment for *Helicobacter pylori* infection. *Therap. Adv. Gastroenterol.* 2016; **9**: 437–48.
- 23 Hsu PI, Lai KH, Hsu PN *et al.* *Helicobacter pylori* infection and the risk of gastric malignancy. *Am. J. Gastroenterol.* 2007; **102**: 725–30.
- 24 Wu DC, Kuo CH, Tsay FW, Hsu WH, Chen A, Hsu PI. A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for *Helicobacter Pylori* Infection. *Medicine (Baltimore).* 2016; **95**: e2698.
- 25 Yu L, Luo L, Long X, Liang X *et al.* Susceptibility-guided therapy for *Helicobacter pylori* infection treatment failures. *Therap. Adv. Gastroenterol.* 2019; **12**: 1756284819874922.
- 26 López-Góngora S, Puig I, Calvet X *et al.* Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for *Helicobacter pylori* infection. *J. Antimicrob. Chemother.* 2015; **70**: 2447–55.
- 27 Saracino IM, Pavoni M, Zullo A *et al.* Antibiotic Resistance and Therapy Outcome in *H. pylori* Eradication Failure Patients. *Antibiotics (Basel).* 2020; **9**: 121.
- 28 Liang CM, Tai WC, Hsu PI *et al.* Trend of changes in antibiotic resistance in *Helicobacter pylori* from 2013 to 2019: a multicentre report from Taiwan. *Therap. Adv. Gastroenterol.* 2020; **13**: 1756284820976990.
- 29 Ge R, Chen Z, Zhou Q. The actions of bismuth in the treatment of *Helicobacter pylori* infections: an update. *Metallomics* 2012; **4**: 239–43.
- 30 Dore MP, Lu H, Graham DY. Role of bismuth in improving *Helicobacter pylori* eradication with triple therapy. *Gut* 2016; **65**: 870–8.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1 The previous failed eradication regimens of all patients.